# An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

> **NCT02882126** · PHASE4 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Subcutaneous Treprostinil

## Key facts

- **NCT ID:** NCT02882126
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882126, "An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02882126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*